Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
GLP-1 agonist-S so called “Wonder Medicines “such as Ozempic or Wegven that help individuals to lower blood sugar levels and lose weight – according to a new study, convey an important results for some patients, but not all.
In order to investigate why some people do not benefit from GLP 1 agonists as much as others, the researchers observed 92 participants with type 2 diabetes in Japan in their first year of taking GLP 1 medication. Her ResultsToday published within clinical diabetes and health care, indicates that people who are to be overeated for external reasons – such as the sight or smell of delicious food – the chances that you will react well to the medication in the long term, more to the medication for emotional reasons.
Who will benefit the most from GLP 1 medication?
“The evaluation of eating behavior before treatment can help to predict who will benefit the most from GLP-1 receptor agonist therapy,” said Daisuke Yabe, senior author of the study and professor of diabetes, endocrinology and nutrition at the University of Kyoto. “GLP-1 receptor agonists are effective for people with weight gain or increased blood sugar levels due to overeating that are triggered by external stimuli. However, their effectiveness is less expected when emotional food is the main cause.”
The team revealed this by collecting data on the body weight and composition, nutrition and information from participants such as blood sugar, cholesterol and relationship with food at the beginning of treatment, three months later and a year later. They focused on emotional food (food in response to negative emotions), external meals (eating because the food looks good) and reserved food (control the diet to lose weight). While it may seem contradictory, according to the researchers, excessive reserved meals can actually lead to a disturbed meal.
In the course of the year, the participants experienced a statistically significant loss of body weight and a lowered cholesterol and body fat percentage without changing the mass of the skeletal muscle. During the blood sugar level, the improvement was not statistically significant. However, there were some variations that depend on eating behavior. Three months after the start of the treatment, the participants reported more reserved food and less external or emotional food. By the end of the year, however, the participants had returned to their original reserved and emotional eating habits.
“A possible explanation is that emotional food is more influenced by psychological factors that may not be treated directly by the agonist GLP 1 receptor therapy,” said Takehiro Kato, the second author of the article and a researcher from the GIFU University, “People with prominent emotional meal tendencies may require additional behavior or psychological support.”
External food reduced during the treatment year
The participants reported that a reduced exterior search was eaten all year round, and people who had a high degree of external food at the beginning of treatment saw the greatest advantages of blood sugar levels and weight loss. On the other hand, at the beginning and the drug advantages of the 12-month brand, the team identified no connection between emotional or reserved dining values.
“While our study provides for a possible connection between external eating behavior and treatment reaction to GLP-1 receptor agonists, these results remain for the time being,” said Yabe. In addition, the team’s study was observed and the participants themselves reported, which means that the researchers revealed a potential association and no causation.
“Further evidence is required before you can be implemented in clinical practice. If future large or randomized controlled studies validate this relationship and simple behavioral reviews become a valuable component in optimizing the treatment strategies,” Yabe concluded.
